Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 1/10

vs
industry
vs
history
Cash to Debt No Debt
NYMX's Cash to Debt is ranked higher than
89% of the 900 Companies
in the Global Biotechnology industry.

( Industry Median: 83.08 vs. NYMX: No Debt )
NYMX' s 10-Year Cash to Debt Range
Min: 0.25   Max: No Debt
Current: No Debt

Equity to Asset -7.57
NYMX's Equity to Asset is ranked lower than
54% of the 742 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. NYMX: -7.57 )
NYMX' s 10-Year Equity to Asset Range
Min: -7.57   Max: 1
Current: -7.57

-7.57
1
F-Score: 1
Z-Score: -168.20
M-Score: 99999999.99
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 4/10

vs
industry
vs
history
Operating margin (%) -145.43
NYMX's Operating margin (%) is ranked higher than
67% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -71.36 vs. NYMX: -145.43 )
NYMX' s 10-Year Operating margin (%) Range
Min: -20470.59   Max: -145.43
Current: -145.43

-20470.59
-145.43
Net-margin (%) -146.14
NYMX's Net-margin (%) is ranked higher than
67% of the 790 Companies
in the Global Biotechnology industry.

( Industry Median: -59.60 vs. NYMX: -146.14 )
NYMX' s 10-Year Net-margin (%) Range
Min: -20570.59   Max: -146.14
Current: -146.14

-20570.59
-146.14
ROA (%) -508.18
NYMX's ROA (%) is ranked lower than
52% of the 889 Companies
in the Global Biotechnology industry.

( Industry Median: -17.36 vs. NYMX: -508.18 )
NYMX' s 10-Year ROA (%) Range
Min: -618.27   Max: -48.41
Current: -508.18

-618.27
-48.41
ROC (Joel Greenblatt) (%) -37576.92
NYMX's ROC (Joel Greenblatt) (%) is ranked lower than
52% of the 861 Companies
in the Global Biotechnology industry.

( Industry Median: -243.56 vs. NYMX: -37576.92 )
NYMX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -60425   Max: -154.81
Current: -37576.92

-60425
-154.81
Revenue Growth (%) 71.00
NYMX's Revenue Growth (%) is ranked higher than
98% of the 623 Companies
in the Global Biotechnology industry.

( Industry Median: -1.80 vs. NYMX: 71.00 )
NYMX' s 10-Year Revenue Growth (%) Range
Min: 0   Max: 115.4
Current: 71

0
115.4
EBITDA Growth (%) -11.20
NYMX's EBITDA Growth (%) is ranked higher than
73% of the 598 Companies
in the Global Biotechnology industry.

( Industry Median: -10.50 vs. NYMX: -11.20 )
NYMX' s 10-Year EBITDA Growth (%) Range
Min: -20.6   Max: 24.6
Current: -11.2

-20.6
24.6
EPS Growth (%) -11.20
NYMX's EPS Growth (%) is ranked higher than
75% of the 630 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. NYMX: -11.20 )
NYMX' s 10-Year EPS Growth (%) Range
Min: -17.6   Max: 23.3
Current: -11.2

-17.6
23.3
» NYMX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q3 2012

NYMX Guru Trades in Q3 2012

George Soros Sold Out
» More
Q3 2013

NYMX Guru Trades in Q3 2013

Jim Simons 35,500 sh (New)
» More
Q4 2013

NYMX Guru Trades in Q4 2013

Jim Simons 43,300 sh (+21.97%)
» More
Q1 2014

NYMX Guru Trades in Q1 2014

Jim Simons 26,506 sh (-38.79%)
» More
» Details

Insider Trades

Latest Guru Trades with NYMX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
George Soros 2012-09-30 Sold Out 0.0036%$5.9 - $6.88 $ 4.93-22%0
George Soros 2012-06-30 New Buy$6.5 - $8.39 $ 4.93-35%38400
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/S 52.30
NYMX's P/S is ranked higher than
65% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 19.16 vs. NYMX: 52.30 )
NYMX' s 10-Year P/S Range
Min: 51.2   Max: 729
Current: 52.3

51.2
729
EV-to-EBIT -25.96
NYMX's EV-to-EBIT is ranked lower than
51% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. NYMX: -25.96 )
NYMX' s 10-Year EV-to-EBIT Range
Min: 0   Max: 0
Current: -25.96

Current Ratio 0.18
NYMX's Current Ratio is ranked lower than
53% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 4.02 vs. NYMX: 0.18 )
NYMX' s 10-Year Current Ratio Range
Min: 0.12   Max: 42.02
Current: 0.18

0.12
42.02
Quick Ratio 0.18
NYMX's Quick Ratio is ranked lower than
52% of the 892 Companies
in the Global Biotechnology industry.

( Industry Median: 3.74 vs. NYMX: 0.18 )
NYMX' s 10-Year Quick Ratio Range
Min: 0.09   Max: 42.02
Current: 0.18

0.09
42.02

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 0.20
NYMX's Price/Median PS Value is ranked higher than
98% of the 956 Companies
in the Global Biotechnology industry.

( Industry Median: 1.91 vs. NYMX: 0.20 )
NYMX' s 10-Year Price/Median PS Value Range
Min: 0.27   Max: 2.12
Current: 0.2

0.27
2.12
Forward Rate of Return (Yacktman) -0.40
NYMX's Forward Rate of Return (Yacktman) is ranked higher than
88% of the 738 Companies
in the Global Biotechnology industry.

( Industry Median: -10.54 vs. NYMX: -0.40 )
NYMX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -10.2   Max: 45
Current: -0.4

-10.2
45

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NY2.Germany
Nymox Pharmaceutical Corporation was incorporated under the Canada Business Corporations Act in May 1995. The Company operates in one reportable segment - the research and development of products for the aging population. The Company conducts R&D and manufacturing for NicAlert and TobacAlert. It is a biopharmaceutical Corporation with three proprietary products on the market, and significant R&D pipeline of products in development. The Company has U.S. and global patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. It is developing new treatments for bacterial infections in humans. NicAlert received clearance from the U.S. FDA and is also certified with a CE Mark in Europe. TobacAlert is the first test of its kind to measure second and third hand smoke exposure in individuals. The Company has developed AlzheimAlert, a urinary test that aids physicians in the diagnosis of Alzheimer's disease. The Company is developing NX-1207, a novel treatment for benign prostatic hyperplasia which is in Phase 3 trials in the U.S. An open-label U.S. re-injection safety study of NX-1207 for BPH was started in July of 2011 and reached completion of its primary endpoint assessment in January 2013. The company is developing new antibacterial agents for the treatment of bacterial infections in humans, including a treatment for E-coli O157:H7 bacterial contamination in meat and other food and drink products. The Company is subject to continuing potential product liability risks.
» More Articles for NAS:NYMX

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
Nymox Announces Positive Efficacy Results in Phase 3 Repeat Injection Trial of NX-1207 for BPH Jul 22 2014
9:30 am Nymox Pharma announces positive efficacy results in Phase 3 repeat injection trial of... Jul 22 2014
Biotech Stock Mailbag: AcelRx, Yellen Aftermath, Nymox Jul 18 2014
Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study Jul 15 2014
Nymox completes enrollment for second BPH re-injection study Jul 15 2014
Nymox Announces Completion of Enrollment for Second BPH Re-Injection Study Jul 15 2014
Nymox Reports Positive Update on Nerve Sparing and Sexual Function Preservation in Men Treated With... Jun 17 2014
Nymox Reports Positive New Safety Study Data for Phase 3 BPH Drug Jun 11 2014
Nymox reports results on side effect profile of NX-1207 treatment May 21 2014
Nymox Reports New Results on Favorable Side Effect Profile of NX-1207 Treatment May 21 2014
Nymox Reports First Quarter 2014 Financial Results May 15 2014
Nymox Pharmaceutical Late- Stage Clinical Trials Substantiating Investor Interest; Analyst Report by... May 14 2014
Nymox reports NX-1207 Phase 2 treatment 'positive' results May 13 2014
Nymox Reports Positive Results Showing That NX-1207 Treatment for Prostate Cancer Does Not Affect... May 13 2014
Nymox completes second pivotal phase 3 NX-1207 trial for BPH May 08 2014
Nymox Announces Completion of Second Pivotal Phase 3 NX-1207 Trial for BPH May 08 2014
Nymox Announces Positive New Prostate Cancer Clinical Trial Results May 06 2014
Incorrect biopsy results cloud Nymox Pharma prostate cancer study Apr 30 2014
Nymox Reports Top-Line Results for Localized Prostate Cancer Study Apr 30 2014
NYMOX PHARMACEUTICAL CORP Financials Mar 20 2014

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Email Hide